PMID- 37464212
OWN - NLM
STAT- MEDLINE
DCOM- 20230818
LR  - 20230909
IS  - 1179-2000 (Electronic)
IS  - 1177-1062 (Linking)
VI  - 27
IP  - 5
DP  - 2023 Sep
TI  - Prognostic and Clinical Significance of Human Leukocyte Antigen Class I 
      Expression in Breast Cancer: A Meta-Analysis.
PG  - 573-582
LID - 10.1007/s40291-023-00664-z [doi]
AB  - BACKGROUND: The value of human leukocyte antigen (HLA; also known as major 
      histocompatibility complex) class I expression for the prediction of breast 
      cancer survival outcomes remains unclear. We conducted a meta-analysis to explore 
      the prognostic significance of this expression. MATERIALS AND METHODS: We 
      searched electronic databases to identify reports on associations of HLA class I 
      protein or mRNA expression with survival outcomes and clinicopathological factors 
      in the breast cancer context. Pooled hazard ratios (HRs) and odds ratios (ORs) 
      with 95% confidence intervals (CIs) were used to conduct a quantitative 
      meta-analysis. RESULTS: The sample comprised eight studies involving 3590 
      patients. Only the classical HLA class Ia (HLA-ABC) molecules studies were 
      included in this meta-analysis. Elevated HLA class I protein expression was found 
      to be significantly related to better disease-free survival (DFS) (HR 0.58, 95% 
      CI 0.35-0.95, P = 0.03), particularly among patients with triple-negative breast 
      cancer (TNBC) (HR 0.31, 95% CI 0.18-0.52, P < 0.001), but not to overall 
      survival. It was also associated with estrogen receptor (ER) negativity (OR 1.71, 
      95% CI 1.24-2.35, P = 0.001), progesterone receptor (PR) negativity (OR 1.49, 95% 
      CI 1.22-1.81, P < 0.001), human epidermal growth factor receptor 2 (HER2) 
      positivity (OR 1.51, 95% CI 1.18-1.94, P = 0.001), TNBC (OR 1.68, 95% CI 
      1.15-2.45, P < 0.01), high Ki-67 indices (OR 2.06, 95% CI 1.62-2.61, P < 0.001), 
      and high nuclear grades (OR 2.67, 95% CI 2.17-3.29, P < 0.001). CONCLUSION: This 
      meta-analysis demonstrated that enhanced HLA class I protein expression is 
      significantly associated with the better DFS of patients with breast cancer, 
      especially TNBC, as well as with ER and PR negativity, HER2 positivity, TNBC, and 
      high Ki-67 indices and nuclear grades. The immune target HLA class I may serve as 
      a prognostic indicator for breast cancer.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Qiao, Weiqiang
AU  - Qiao W
AD  - Department of Breast Surgery, The First Affiliated Hospital and College of 
      Clinical Medicine of Henan University of Science and Technology, Jinghua Road No. 
      24, Luoyang, 471000, China.
FAU - Jia, Zhiqiang
AU  - Jia Z
AD  - Henan Provincial Key Medical Laboratory of Tissue Damage and Repair, The Second 
      Affiliated Hospital of Henan University of Science and Technology, Luoyang, 
      471000, China.
FAU - Guo, Wanying
AU  - Guo W
AD  - Department of Breast Surgery, The First Affiliated Hospital and College of 
      Clinical Medicine of Henan University of Science and Technology, Jinghua Road No. 
      24, Luoyang, 471000, China.
FAU - Liu, Qipeng
AU  - Liu Q
AD  - Department of Breast Surgery, The First Affiliated Hospital and College of 
      Clinical Medicine of Henan University of Science and Technology, Jinghua Road No. 
      24, Luoyang, 471000, China.
FAU - Guo, Xiao
AU  - Guo X
AD  - Department of Breast Surgery, The First Affiliated Hospital and College of 
      Clinical Medicine of Henan University of Science and Technology, Jinghua Road No. 
      24, Luoyang, 471000, China.
FAU - Deng, Miao
AU  - Deng M
AUID- ORCID: 0000-0001-7146-0619
AD  - Department of Breast Surgery, The First Affiliated Hospital and College of 
      Clinical Medicine of Henan University of Science and Technology, Jinghua Road No. 
      24, Luoyang, 471000, China. dengmiao1973@163.com.
LA  - eng
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230718
PL  - New Zealand
TA  - Mol Diagn Ther
JT  - Molecular diagnosis & therapy
JID - 101264260
RN  - 0 (Ki-67 Antigen)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/metabolism
MH  - *Triple Negative Breast Neoplasms
MH  - Prognosis
MH  - Ki-67 Antigen
MH  - Clinical Relevance
MH  - Receptor, ErbB-2/genetics/metabolism
MH  - Disease-Free Survival
EDAT- 2023/07/19 01:06
MHDA- 2023/08/18 06:43
CRDT- 2023/07/18 23:34
PHST- 2023/07/03 00:00 [accepted]
PHST- 2023/08/18 06:43 [medline]
PHST- 2023/07/19 01:06 [pubmed]
PHST- 2023/07/18 23:34 [entrez]
AID - 10.1007/s40291-023-00664-z [pii]
AID - 10.1007/s40291-023-00664-z [doi]
PST - ppublish
SO  - Mol Diagn Ther. 2023 Sep;27(5):573-582. doi: 10.1007/s40291-023-00664-z. Epub 
      2023 Jul 18.